Work at Boehringer Ingelheim Pharma GmbH & Co. KG has led to the synthesis of pyrazolo[5,1-f][1,2,4]triazin-4-ones acting as NADPH oxidase 4 (NOX4) inhibitors. As such, they are described as potentially useful for the treatment of liver disease, portal hypertension, viral infection, cancer, interstitial lung diseases, retinopathy, inflammation and fibrosis.
Academia Sinica and National Cheng Kung University have divulged peptides and their lipid nanoparticles formed on encapsulation by 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), cholesterol and DSPE-PEG2K liposomes reported to be useful for the treatment of cancer.
Beijing Innocare Pharma Tech Co. Ltd. and Innocare Pharma Inc. have patented molecular glue degraders acting as VAV1 degradation inducers. They are reported to be useful for the treatment of autoimmune disease and inflammatory disorders.
Shanghai Huilun Pharmaceutical Co. Ltd. has synthesized potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators. They are reported to be useful for the treatment of epilepsy, neuropathic pain, ischemic stroke and neurodegeneration.
Biohaven Therapeutics Ltd. has presented prodrugs of betahistine reported to be useful for the treatment of obsessive-compulsive disorder, trichotillomania, Tourette syndrome, amyotrophic lateral sclerosis, multiple sclerosis and more.
Suzhou Bioreinno Biotechnology Ltd. Co. has identified antibody-drug conjugates comprising antibodies covalently linked to a cytotoxic drug through a linker. They are reported to be useful for diagnosis and treatment of cancer.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has disclosed crystalline forms of phosphodiesterase PDE4B2 inhibitors. They are reported to be useful for the treatment of chronic obstructive pulmonary disease, interstitial lung diseases and asthma.
Shandong Xiansheng Maidejin Biological Pharmaceutical Co. Ltd. has prepared and tested cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Chia Tai Qingjiang Pharmaceutical Co. Ltd. has synthesized peptide epoxyketone compounds acting as proteasome inhibitors. They are reported to be useful for the treatment of systemic lupus erythematosus, ulcerative colitis and rheumatoid arthritis.
RSS